GlassScriptPhysician profile
Katia Moreno
NPI 1538621693
$7,363.11
in general payments reported to CMS, 2019-2025
28 companies · $750 in 2025
The $750 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,163 · 2022: $268 · 2023: $709 · 2024: $473 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.59 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $5,137.60 | 2021-2025 | |
| Daiichi Sankyo INC. | $306.32 | 2022-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $230.20 | 2022-2025 | |
| Abbvie INC. | $199.06 | 2023-2025 | |
| Celgene Corporation | $194.43 | 2023-2025 | Reblozyl, Pomalyst |
| Ipsen Biopharmaceuticals, INC | $149.99 | 2023 | Onivyde |
| Lilly USA, LLC | $146.12 | 2023-2025 | Jaypirca, Retevmo, Verzenio |
| Emd Serono, INC. | $137.41 | 2023 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $104.48 | 2022-2025 | Opdualag, Opdivo |
| Glaxosmithkline, LLC. | $103.08 | 2023-2025 | Ojjaara, Shingrix, Blenrep |
| Rigel Pharmaceuticals, INC. | $92.18 | 2021-2023 | Rezlidhia, Tavalisse |
| Genentech USA, INC. | $87.89 | 2022-2025 | Tecentriq, Itovebi |
| Gilead Sciences, INC. | $60.51 | 2025 | Trodelvy |
| Astellas Pharma US INC | $60.06 | 2024-2025 | Xospata, Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $51.49 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $39.48 | 2022 | |
| Merck Sharp & Dohme LLC | $38.07 | 2022-2025 | Keytruda |
| Amgen INC. | $31.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.32 | 2025 | Ninlaro |
| Medtronic, INC. | $23.46 | 2024 | Osteocool Rf Ablation System |
| G1 Therapeutics, INC. | $21.71 | 2023 | Cosela |
| Eisai INC. | $20.20 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $18.67 | 2022 | |
| Karyopharm Therapeutics INC. | $18.01 | 2024 | Xpovio |
| Genzyme Corporation | $17.25 | 2022 | |
| Array Biopharma INC | $16.55 | 2022 | |
| Taiho Oncology, INC. | $15.77 | 2024 | |
| Seagen INC. | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katia Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.